Corgenix and NIH announce collaboration

The two-year study will use the Corgenix hyaluronic acid (HA) test kit alone and in combination with other liver fibrosis biomarkers, to develop a predictive model for liver fibrosis in nonalcoholic steatohepatitis (NASH) patients. NASH patients are typically diagnosed using invasive liver biopsy procedures. The Corgenix-National Institutes of Diabetes and Digestive and Kidney Diseases study is focused on developing a non-invasive method of diagnosis.

Douglass Simpson, president and CEO of Corgenix, said: “We are very excited about our collaboration with the National Institutes of Health (NIH). This is a definitive study that will apply our HA product to a very important and clearly under-diagnosed condition that affects a significant percentage of the US population. With the rate of obesity in the US continuing to increase, the prevalence of NASH will increase as well, and it will be even more important to have effective, non-invasive methods for assessment.”